Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etiocholanedione is a naturally occurring steroid and an endogenous metabolite of androgens such as testosterone, dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), and androstenedione. It is also known as the C5 epimer of androstanedione. Unlike other androgens, it lacks androgenic activity but exhibits distinct biological effects including potent haematopoietic activity and antiobesity effects in animal models and humans. Etiocholanedione cannot be further metabolized into active steroid hormones like estrogens or more potent androgens. It has been studied for its ability to promote weight loss in clinical settings. Mechanistically, it acts as a neurosteroid with inhibitory effects on glycine-induced chloride currents in neurons[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etiocholanedione.